ATRIUM THERAPEUTICS INC
RNANASDAQTrading Snapshot
- Day Range
- $8.34 – $8.65
- 52-Week Range
- $7.49 – $16.77
- Volume (shares)
- 35,724.373
- Avg Volume (shares)
- —
- Shares Outstanding
- 17.1M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $3M
- P/E Ratio
- -2.2
- P/S Ratio
- 6.1x
- EPS (TTM)
- $-5.45
- Dividend Yield
- 0.00%
ATRIUM THERAPEUTICS INC
RNAFinancial history unavailable.
StockOtter · stockotter.spaceAbout ATRIUM THERAPEUTICS INC
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants -- -- Initial proof of concept data expected in second half of 2027 -- SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc.
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive A
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty pe
Atrium Therapeutics (NASDAQ: RNA) lines up $50 million private placement
What happened Atrium Therapeutics, Inc. (NASDAQ: RNA) said on October 7, 2026, that it entered a securities purchase agreement. The company said the financing is expected to bring in about $50 million in gross proceeds b
Atrium Therapeutics Announces $50 Million Private Placement
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart
Avidity Biosciences (NASDAQ:RNA) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
Shares of Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $12.37 and traded as low as $7.78. Avidity